Amanote Research
Register
Sign In
Prm2 - Identification of Dose-Escalation in Biologic Therapy Based on Claims Data: The Example of Patients With Inflammatory Bowel Disease
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.2127
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
A Groth
A Brandes
A Fuchs
B Deiters
B Ratsch
T Wilke
B Bokemeyer
Publisher
Elsevier BV
Related search
Inflammatory Bowel Disease in the Clinic: Escalation and De-Escalation of Therapy: A Longitudinal Case-Based Discussion
Journal of Gastroenterology and Hepatology
Hepatology
Gastroenterology
Rapid Response to Vedolizumab Therapy in Biologic-Naïve Patients With Inflammatory Bowel Diseases
Clinical Gastroenterology and Hepatology
Hepatology
Gastroenterology
Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease
Inflammatory Bowel Diseases
Allergy
Immunology
Gastroenterology
The Effect of Anti-TNF Therapy on Thyroid Function in Patients With Inflammatory Bowel Disease
Endocrine Journal
Endocrinology
Metabolism
Diabetes
Which Patients With Inflammatory Bowel Disease Should Receive Combination Therapy?
Expert Review of Gastroenterology and Hepatology
Hepatology
Gastroenterology
Potential Modulation of Disease Activity Indices and Inflammatory Biomarkers in Patients With Active Inflammatory Bowel Disease on Melatonin Adjuvant Therapy
Asian Journal of Pharmaceutical and Clinical Research
Pharmacology
Pharmaceutical Science
Prostaglandins in Inflammatory Bowel Disease Therapy
Canadian Journal of Gastroenterology
The Effect of a Mindfulness-Based Therapy on Different Biomarkers Among Patients With Inflammatory Bowel Disease: A Randomised Controlled Trial
Scientific Reports
Multidisciplinary
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients With Inflammatory Bowel Diseases
Journal of Clinical Medicine
